| Objective: To observe the clinical and experiment effect of QianLieNing(QLN) in treating Benign Prostatic Hyperplasia and explore its mechanism of effect.Methods: The study is involved 57 cases Benign Prostatic Hyperplasia patients lasting for 2 months. All the patients were divided into two groups randomly: treating group(29 cases) and control group(28 cases).The control group was dosed with LongBiShu(LBS); the treating group were dosed with QLN. The changes of clinical symptom,I-PSS(International Prostate Symptom Score),QOL(Quality of Life) ,Qmax(Maximum Flow Rate) and the volume of prostate were observed before and after treatment in the groups. Experiment use rats prostate hyperplasia, measure prostate weight and prostate Index, analysis of the efficiency of the drug for benign prostatic hyperplasia.Results: In the treating group, there were remarkable differences in the melioration of clinical symptoms and Qmax, the decreasing of I-PSS, QOL compared with before treatment, but it has little influence on diminishing the volume of prostate. It is superior to the control group in decreasing I-PSS, QOL .and raising Qmax, and there were remarkable differences in the melioration of some of clinical symptoms compared with the control group. The experimental results show that compared with the model group, High dose and middle dose group can decrease prostate weight, inhibit prostate hyperplasia.Conclusion: According to the results, we can conclude that QianLieNing can improve the quality of life and diminish the volume of prostate of patients. It's an effective prescription to BPH by alleviating clinical symptoms. QianLieNing is easy to use, safe and effective, if combined with modern percutaneous absorption technology, it will have even broader prospects. |
PDF Full Text Request